Zafgen (ZFGN) has an average broker rating of 2.5, which is interpreted as a Buy, as rated by 6 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Zafgen (ZFGN) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $6 and the lowest price target forecast is $3. The average forecast of all the analysts is $4.67 and the expected standard deviation is $1.53.
Company shares have received an average consensus rating of Hold for the current week Also, In a research note released to the investors, Cowen & Company downgrades its rating on Zafgen (NASDAQ:ZFGN).The analysts at the brokerage house have a current rating of Market Perform on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on July 20, 2016.
Zafgen (NASDAQ:ZFGN): The stock opened at $2.99 and touched an intraday high of $3.15 on Wednesday. During the day, the stock corrected to an intraday low of $2.99, however, the bulls stepped in and pushed the price higher to close in the green at $3.05 with a gain of 2.35% for the day. The total traded volume for the day was 492,929. The stock had closed at $2.98 in the previous trading session.
Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Companys lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity. Beloranib is in Phase III stage of development for obesity and hyperphagia in patients with PWS; completed Phase II clinical trial for HIAO, and is in Phase IIb stage of development for severe obesity in the general population. The Companys other product candidate, ZGN-839, is in pre-clinical development stage. The Company is also evaluating the additional MetAP2 inhibitors beyond Beloranib as potential development candidates for the treatment of severe obesity.